Galderma R&D facility underscores commitment

Article

Sophia Antipolis, France - Galderma's commitment to dermatology, and dermatology only, is nowhere more evident than in its sprawling, approximately 24,000-square-foot research and development facility in the south of France.

Related Videos
Related Content

A Hairy Q&A With Jerry Shapiro, MD

September 30th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Evaluating Efficacy of Trifarotene in Latin American Patients With Acne

September 30th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Understanding Eyebrow and Eyelash Hair Loss in Severe Alopecia Areata

September 29th 2023

Incyte to Present Numerous Studies at EADV 2023

September 29th 2023

A Hairy Q&A With Jerry Shapiro, MD

September 30th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Evaluating Efficacy of Trifarotene in Latin American Patients With Acne

September 30th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Understanding Eyebrow and Eyelash Hair Loss in Severe Alopecia Areata

September 29th 2023

Incyte to Present Numerous Studies at EADV 2023

September 29th 2023

A Hairy Q&A With Jerry Shapiro, MD

September 30th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Evaluating Efficacy of Trifarotene in Latin American Patients With Acne

September 30th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Understanding Eyebrow and Eyelash Hair Loss in Severe Alopecia Areata

September 29th 2023

Incyte to Present Numerous Studies at EADV 2023

September 29th 2023
© 2023 MJH Life Sciences

All rights reserved.